Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · IEX Real-Time Price · USD
13.02
+0.01 (0.04%)
Apr 25, 2024, 11:25 AM EDT - Market open
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 13.78, with a low estimate of 10 and a high estimate of 19. The average target predicts an increase of 5.88% from the current stock price of 13.02.
Analyst Consensus: Buy
* Price targets were last updated on Mar 8, 2024.
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades $14 | Sell → Hold | Upgrades | $14 | +7.57% | Mar 8, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $12 → $19 | Hold → Buy | Upgrades | $12 → $19 | +45.99% | Feb 12, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $10 → $11 | Hold | Maintains | $10 → $11 | -15.48% | Feb 5, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +30.62% | Feb 5, 2024 |
| Barclays | Barclays | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +15.25% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
16.07B
from 15.85B
Increased by 1.39%
Revenue Next Year
16.50B
from 16.07B
Increased by 2.73%
EPS This Year
2.42
from -0.50
EPS Next Year
2.65
from 2.42
Increased by 9.42%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 16.8B | 17.3B | 18.0B |
| Avg | 16.1B | 16.5B | 16.9B |
| Low | 15.0B | 15.3B | 15.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 6.3% | 7.8% | 9.1% |
| Avg | 1.4% | 2.7% | 2.5% |
| Low | -5.0% | -4.5% | -6.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.53 | 2.81 | 2.96 |
| Avg | 2.42 | 2.65 | 2.80 |
| Low | 2.25 | 2.49 | 2.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 16.1% | 11.7% |
| Avg | - | 9.4% | 5.5% |
| Low | - | 2.7% | -2.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.